497 related articles for article (PubMed ID: 21030459)
21. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
22. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
Kim S; Kim TM; Kim DW; Go H; Keam B; Lee SH; Ku JL; Chung DH; Heo DS
J Thorac Oncol; 2013 Apr; 8(4):415-22. PubMed ID: 23344087
[TBL] [Abstract][Full Text] [Related]
24. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
25. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.
Chand D; Yamazaki Y; Ruuth K; Schönherr C; Martinsson T; Kogner P; Attiyeh EF; Maris J; Morozova O; Marra MA; Ohira M; Nakagawara A; Sandström PE; Palmer RH; Hallberg B
Dis Model Mech; 2013 Mar; 6(2):373-82. PubMed ID: 23104988
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
27. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.
Schönherr C; Ruuth K; Yamazaki Y; Eriksson T; Christensen J; Palmer RH; Hallberg B
Biochem J; 2011 Dec; 440(3):405-13. PubMed ID: 21838707
[TBL] [Abstract][Full Text] [Related]
28. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
[TBL] [Abstract][Full Text] [Related]
29. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
30. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.
Lucena-Araujo AR; Moran JP; VanderLaan PA; Dias-Santagata D; Folch E; Majid A; Kent MS; Gangadharan SP; Rangachari D; Huberman MS; Kobayashi SS; Costa DB
Lung Cancer; 2016 Sep; 99():17-22. PubMed ID: 27565908
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7.
Takeoka K; Okumura A; Maesako Y; Akasaka T; Ohno H
Cancer Genet; 2015 Mar; 208(3):85-90. PubMed ID: 25766836
[TBL] [Abstract][Full Text] [Related]
32. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB
J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245
[TBL] [Abstract][Full Text] [Related]
33. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
[TBL] [Abstract][Full Text] [Related]
34. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
[TBL] [Abstract][Full Text] [Related]
35. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
36. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
[TBL] [Abstract][Full Text] [Related]
38. Exploring the structural and functional impact of the ALK F1174L mutation using bioinformatics approach.
Kumar A; Ramanathan K
J Mol Model; 2014 Jul; 20(7):2324. PubMed ID: 24952065
[TBL] [Abstract][Full Text] [Related]
39. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]